Travere Therapeutics, Inc. TVTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 98.6%+2.6pp | 97.9%+1.2pp | 97.6%+2.4pp | 96.9%+2.2pp | 96%+1.7pp | |
| Operating margin | -10.6%+72.4pp | -12.8%+126pp | -20.9%+155pp | -51.6%+170pp | -83.1%+193pp | |
| Returns | ||||||
| Return on invested capital | -118%+268pp | -96.2%+151pp | —— | -636.6%+308pp | -385.6%+357pp | |
| Efficiency | ||||||
| Asset turnover | 1×+0.5× | 0.8×+0.5× | 0.8×+0.5× | 0.6×+0.3× | 0.5×+0.2× | |
| Liquidity | ||||||
| Current ratio | 3.1×+1.1× | 2.7×+0.7× | 2.7×+1.0× | 2×-1.0× | 2.1×-0.7× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×-2.6× | 0.1×-1.4× | 0.2×— | 2.7×+1.0× | 2.7×+2.4× | |
| Net debt / EBITDA | -3.9×— | —— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $1.07+189% | $1.29+71.9% | $0.72+283% | $0.37+88.4% | $0.37-61.3% | |
| Valuation | ||||||
| Market capitalization | $2.74B+72.3% | $3.42B+125% | $2.13B+96.5% | $1.35B+113% | $1.59B+167% | |
| Price / sales | 5.1×-0.7× | 7×+0.5× | 4.9×-0.4× | 4.1×+0.5× | 5.8×+2.0× | |
| Price / book | 27.8×-20.7× | 29.8×+4.1× | 29×— | 41.3×-0.5× | 48.4×+40.4× | |
| EV / EBITDA | 166.4×— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Travere Therapeutics, Inc.'s profit margins?
- Travere Therapeutics, Inc. (TVTX) runs a 98.6% gross margin and a -10.6% operating margin, with a -20.3% net margin.
- Where do Travere Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Travere Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.